Neuschwander‐Tetri, Brent A.

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†

Neuschwander‐Tetri, B. A. (2010) · Hepatology

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 1,077

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial†‡§

Harrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology

Liver Disease Diagnosis and TreatmentPharmacology and Obesity Treatment

Cited by 470

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity

Fibroblast Growth Factor ResearchLiver Disease Diagnosis and Treatment

Cited by 257

Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials

Brunt, E. M., Kleiner, D. E., Wilson, L. A., Sanyal, A. J., Neuschwander‐Tetri, B. A., & for the Nonalcoholic Steatohepatitis Clinical Research Network (2019) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 154